ONCT 534
Alternative Names: GTX 534; GTx-534; ONCT-534Latest Information Update: 19 Jun 2024
At a glance
- Originator University of Tennessee Research Foundation
- Developer Oncternal Therapeutics, Inc.
- Class Antiandrogens; Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor antagonists; Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 31 Dec 2023 Oncternal Therapeutics has patent protection for ONCT 534 in Australia, Japan, Canada, China, Europe (validated in Great Britain, France and Germany), India, and Russia
- 31 Dec 2023 Oncternal Therapeutics has pending patent application for ONCT 534 outside of the US
- 26 Oct 2023 ONCT 534 receives Fast Track designation for Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in USA